Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulrik Lassen

Showing results (1-10 of 159) with videos related to

Pageof 16
Sort By:
The Lancet. Oncology|August 6, 2019
Combining PARP inhibition with PD-1 inhibitorsUlrik Lassen
ESMO Open|December 6, 2019
How I treat <i>NTRK</i> gene fusion-positive cancersUlrik Lassen
The Lancet. Oncology|December 16, 2019
Entrectinib for ROS1 fusion-positive NSCLC and NTRK fusion-positive solid tumoursUlrik Lassen
Lung Cancer (Amsterdam, Netherlands)|June 12, 2002
FDG-PET imaging in small cell lung cancer: any value?Ulrik Lassen
Cell Reports. Medicine|June 21, 2023
Putting data to work for precision medicineAndreas Bjerrum, Ulrik Lassen
Drugs|January 5, 2021
Detecting and Targeting NTRK Fusions in Cancer in the Era of Tumor Agnostic OncologyKristoffer S Rohrberg, Ulrik Lassen
Ugeskrift for Laeger|November 15, 2014
[The genome and cancer treatment]Finn Cilius Nielsen, Ulrik Lassen
Acta Oncologica (Stockholm, Sweden)|February 23, 2026
Realising precision oncology through shared real-world data infrastructureAndreas Bjerrum, Andreas Fanø, Ulrik Lassen
The New England Journal of Medicine|March 11, 2011
PET-CT in preoperative staging of lung cancerBarbara M Fischer, Ulrik Lassen, Liselotte Højgaard
ESMO Open|September 16, 2017
Hallmarks of glioblastoma: a systematic reviewDorte Schou Nørøxe, Hans Skovgaard Poulsen, Ulrik Lassen
Pageof 16

Showing results (1-10 of 159) with videos related to

Sort By:
Pageof 16
The Lancet. Oncology|August 6, 2019
Combining PARP inhibition with PD-1 inhibitorsUlrik Lassen
ESMO Open|December 6, 2019
How I treat <i>NTRK</i> gene fusion-positive cancersUlrik Lassen
The Lancet. Oncology|December 16, 2019
Entrectinib for ROS1 fusion-positive NSCLC and NTRK fusion-positive solid tumoursUlrik Lassen
Lung Cancer (Amsterdam, Netherlands)|June 12, 2002
FDG-PET imaging in small cell lung cancer: any value?Ulrik Lassen
Cell Reports. Medicine|June 21, 2023
Putting data to work for precision medicineAndreas Bjerrum, Ulrik Lassen
Drugs|January 5, 2021
Detecting and Targeting NTRK Fusions in Cancer in the Era of Tumor Agnostic OncologyKristoffer S Rohrberg, Ulrik Lassen
Ugeskrift for Laeger|November 15, 2014
[The genome and cancer treatment]Finn Cilius Nielsen, Ulrik Lassen
Acta Oncologica (Stockholm, Sweden)|February 23, 2026
Realising precision oncology through shared real-world data infrastructureAndreas Bjerrum, Andreas Fanø, Ulrik Lassen
The New England Journal of Medicine|March 11, 2011
PET-CT in preoperative staging of lung cancerBarbara M Fischer, Ulrik Lassen, Liselotte Højgaard
ESMO Open|September 16, 2017
Hallmarks of glioblastoma: a systematic reviewDorte Schou Nørøxe, Hans Skovgaard Poulsen, Ulrik Lassen
Pageof 16